SINGAPORE-- A proposed $200 million merger between India's Strides Arcolab and Shasun Pharmaceuticals is about to be tested by Shasun's shareholders.
FiercePharma brings you notes on the Asian and emerging markets operations of major drug companies from fourth-quarter earnings calls to explain what C-suite executives are focused on.
SINGAPORE-- The head of Guinea's Ebola-response program wasted no time in announcing approval of broader use of Fujifilm's Avigan (favipiravir) influenza drug for treating early cases of Ebola in the West Africa nation.
Stada Pharm is the latest company to tilt into the Ebola fray with a rapid diagnostic product for use on patients and bodies in the field. Starting in March, the German pharma will begin marketing a test developed and produced by German startup Senova to detect advanced-stage Ebola infection within about 10 minutes. The terms of the partnership for the product were undisclosed.
SINGAPORE-- Pakistan's pharmaceutical industry reportedly has decided to step aside and cease opposition to a government plan to force down the price of certain drugs marketed in the country as of July 1, 2016.
SINGPAPORE-- Merck has confirmed it will move to let Simcere Pharmaceuticals run a high-profile China joint venture aimed at branded generic drugs announced in 2011 and focus instead on its mature products in the local market.
The head of the U.K.'s Trade & Investment Ministry has begun a three-day visit to India to focus on biotech and health issues, beginning with the Bangalore India Bio, the nation's major biotech conference.
SINGAPORE-- India, Indonesia, Thailand and Vietnam are at the bottom in terms of protections for intellectual property, and much of the rest of Asia is ranked near them in an assessment by a U.S. Chamber of Commerce unit. Singapore was ranked in the top 5 in the Pacific region with Australia, Japan, New Zealand and South Korea close behind.
Setting up camp in the Middle East is the trend du jour in Big Pharma, and Merck KGaA is expanding its footprint there by launching its new diabetes education program in the United Arab Emirates.
India's Cipla argued before the Delhi High Court against the Novartis patent for its Onbrez (indacaterol) COPD drug, saying the patent need not be honored because the Swiss drugmaker was not working it in the country and has licensed it to Lupin instead.